- Live market news
- Stocks
- SGMT
Sagimet Biosciences Inc. Series A Common Stock
SGMTStockUnited States
Latest news on SGMTranked by Oyticker for market impact
- 45Impact
SGMT Closes $115M Series A Offering; Dilution and Cash Runway Extended
Sagimet Biosciences closed an underwritten offering of 8.75M Series A shares at $10.00 and 2.75M pre-funded warrants at $9.9999, raising ~$115M gross proceeds to fund clinical-stage development.
SGMTBiopharmaceuticalsHealthcare - 45Impact
Sagimet Biosciences prices $115M Series A equity offering
Clinical-stage biopharmaceutical Sagimet Biosciences priced a $115M underwritten offering of Series A common stock and pre-funded warrants at $10.00/share, expected to close October 1, 2026.
SGMTBiopharmaceuticalsHealthcare - 62Impact
Sagimet's Partner Ascletis Reports Positive 52-Week Phase 3 Data for Denifanstat in Acne
Ascletis presented positive full 52-week results from Phase 3 open-label extension trial of denifanstat (ASC40-304) in moderate-to-severe acne at EADV 2026. Sagimet holds development rights outside China under a licensing agreement.
SGMTBiopharmaceuticalsDermatology
What SGMT filed
- 22 Oct 2026
- 30 Sept 2026
- 30 Sept 2026
Other event
- 13 Aug 2026
- 11 Aug 2026
Investor communication
- 11 Aug 2026
- 20 Jul 2026
- 12 Jun 2026
Shareholder vote results
- 3 Jun 2026
- 12 May 2026
- 12 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.